Journal
ANTIOXIDANTS
Volume 11, Issue 8, Pages -Publisher
MDPI
DOI: 10.3390/antiox11081609
Keywords
COVID-19; oxidative stress; antioxidant enzymes; genetics; anti-oxidative therapies; glutathione; N-acetylcysteine
Funding
- Slovenian Research Agency [P1-0170]
Ask authors/readers for more resources
This article highlights the critical role of oxidative stress in COVID-19, discussing genetic variants within the oxidative stress pathway associated with the disease and exploring the use of antioxidant therapies in clinical trials for COVID-19 treatment, particularly glutathione and N-acetylcysteine.
The coronavirus disease (COVID-19) pandemic is a leading global health and economic challenge. What defines the disease's progression is not entirely understood, but there are strong indications that oxidative stress and the defense against reactive oxygen species are crucial players. A big influx of immune cells to the site of infection is marked by the increase in reactive oxygen and nitrogen species. Our article aims to highlight the critical role of oxidative stress in the emergence and severity of COVID-19 and, more importantly, to shed light on the underlying molecular and genetic mechanisms. We have reviewed the available literature and clinical trials to extract the relevant genetic variants within the oxidative stress pathway associated with COVID-19 and the anti-oxidative therapies currently evaluated in the clinical trials for COVID-19 treatment, in particular clinical trials on glutathione and N-acetylcysteine.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available